RIGL (STOCKS)
Rigel Pharmaceuticals Inc. (New)
$33.420000
+0.570000 (+1.74%)
Prev close: $32.850000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Raul R. Rodriguez
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $619.45M
- Employees
- 164
- P/E (TTM)
- 1.79
- P/B (TTM)
- 1.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
4
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.44 | $0.70 | -0.2570 | -36.87% |
|
Dec 2025 (Q4)
|
$1.15 | $1.27 | -0.1217 | -9.57% |
|
Sep 2025 (Q3)
|
$1.46 | $0.87 | +0.5882 | +67.47% |
|
Jun 2025 (Q2)
|
$3.28 | $2.63 | +0.6484 | +24.64% |
Financial Statements
| Revenues | $299.77M |
| Benefits Costs and Expenses | $177.79M |
| Cost Of Revenue | $19.82M |
| Costs And Expenses | $175.19M |
| Gross Profit | $279.95M |
| Operating Expenses | $155.37M |
| Selling, General, and Administrative Expenses | $118.84M |
| Research and Development | $36.54M |
| Operating Income/Loss | $124.58M |
| Income/Loss From Continuing Operations After Tax | $364.23M |
| Income/Loss From Continuing Operations Before Tax | $121.97M |
| Income Tax Expense/Benefit | -$242.26M |
| Net Income/Loss | $364.23M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $364.23M |
| Net Income/Loss Available To Common Stockholders, Basic | $364.23M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $20.23 |
| Diluted Earnings Per Share | $19.28 |
| Basic Average Shares | 54,410,000 |
| Diluted Average Shares | 57,465,000 |
| Assets | $504.61M |
| Current Assets | $234.03M |
| Cash | $146.70M |
| Inventory | $11.65M |
| Other Current Assets | $75.68M |
| Noncurrent Assets | $270.58M |
| Liabilities | $104.71M |
| Current Liabilities | $89.49M |
| Accounts Payable | $4.49M |
| Wages | $6.01M |
| Other Current Liabilities | $79.00M |
| Noncurrent Liabilities | $15.22M |
| Long-term Debt | $45.00M |
| Equity | $399.90M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $399.90M |
| Liabilities And Equity | $504.61M |
| Net Cash Flow From Operating Activities | $79.27M |
| Net Cash Flow From Operating Activities, Continuing | $79.27M |
| Net Cash Flow From Investing Activities | -$89.79M |
| Net Cash Flow From Investing Activities, Continuing | -$89.79M |
| Net Cash Flow From Financing Activities | -$10.80M |
| Net Cash Flow From Financing Activities, Continuing | -$10.80M |
| Net Cash Flow | -$21.32M |
| Net Cash Flow, Continuing | -$21.32M |
| Comprehensive Income/Loss | $364.10M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $364.11M |
| Other Comprehensive Income/Loss | $27.77M |